secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001104659-24-097127
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel initiates patient enrollment in pivotal Phase 3 SERENITY At-Home trial for BXCL501
--------------------------------------------------------------------------------

- Phase 3 trial evaluates safety of 120 mcg BXCL501 (dexmedetomidine ODF) for acute agitation in bipolar or schizophrenia in the at-home setting.
- Double-blind, placebo-controlled study will enroll ~200 patients; patients self-administer drug/placebo over 12-week period.
- Primary objective is safety; exploratory endpoint modified CGI-C two hours after dosing; trial duration expected 9–12 months.
- No changes to guidance or financial outlook; company previously disclosed substantial doubt about going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924097127/0001104659-24-097127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924097127/tm2423413d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-097127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer